Principal Financial Group Inc. Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Principal Financial Group Inc. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,425 shares of the biopharmaceutical company’s stock after purchasing an additional 800 shares during the quarter. Principal Financial Group Inc. owned 0.11% of Regeneron Pharmaceuticals worth $93,045,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. WPG Advisers LLC lifted its holdings in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $29,000. Board of the Pension Protection Fund acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $31,000. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $664.45 on Thursday. The company has a market cap of $70.25 billion, a PE ratio of 16.19, a P/E/G ratio of 1.45 and a beta of 0.24. The company has a fifty day moving average price of $642.36 and a two-hundred day moving average price of $719.45. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business’s revenue was up 19.0% on a year-over-year basis. During the same quarter last year, the business posted $8.22 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.16 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on REGN. Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Sanford C. Bernstein cut their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Leerink Partners reaffirmed a “market perform” rating and issued a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Finally, Citigroup downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $900.00 to $700.00 in a research report on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $787.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.